Zera®-2 patent of ZIP Solutions also granted in USA

ZIP Solutions –Bionaturis Group- has just been granted with a new patent titled “Protein Body-inducing Polypeptide Sequences” for EEUU, becoming the third patent of the same family, already obtained for Japan and Europe. This patent contributes to a better protection of the Zera Subunit Vaccines 2.0 and Zera DNA Vaccines outstanding applications.

After the granting by The United States Patent and Trademark Office (USPTO), this ZIP Solutions invention is protected in three relevant international markets. The patent family claims the use of second-generation self-assembly fusion sequences, Zera®2, to express and produce recombinant proteins in eukaryotic hosts forming protein bodies. Zera®2 aims to standardize the immune response raised by recombinant vaccines and DNA vaccines plus elimination of the cold-chain by formation of metastable nanostructures.

For further information about this patent, please, click here 

Zera Intein Protein Solutions (ZIP) is all-round bioprocessing, developing and offering highly effective tools for industrial applications of protein-based products such as peptides, recombinant antigens, enzymes, nanobodies, among others. Proprietaries Zera® and Splittera systems – the later subject of an exclusive and worldwide license to a leading multinational company- are optimal solutions to express and purify biological products at industrial scale.

Please, click here to read the Relevant Information (Only in Spanish)

About Bionaturis Group

Bionaturis Group offers premium solutions for human and animal health; it comprises four companies (Bionaturis, Biobide, ZIP Solutions, and BNT Pacific) and two subsidiaries (Biobide USA and BNT China Biosciences) in six different locations around the world. Bionaturis lists on the Spanish stock exchange for SMEs (trading code BNT).


May 29th, 2017|Blog english, Hechos Relevantes|Comments Off on Zera®-2 patent of ZIP Solutions also granted in USA

Bionaturis Group, at the KC Animal Health Investment Forum

The Global Sales Manager at Bionaturis Group, Eli Kehrli, is attending today the commemorative event of the 10th Anniversary of the Kansas City-centered Animal Health Corridor.

The Kansas City-centered Animal Health Corridor is the biggest business and research center devoted to animal health in the world. More than 300 companies are located in this area, considered the “Sillicon Valley” in this sector. With our attendance to this relevant event, in which more than 1,000 experts in the sector are taking part, Bionaturis continues working and strengthening its international strategy.

Bionaturis Group has already presence in USA with the subsidiary of BBD BioPhenix in Maryland and the strategic agreement with Biological Mimetics (BMI) to jointly develop new vaccines for human and animal health applications.

About Bionaturis Group

The Bionaturis Group offers cutting-edge biotechnological drugs and services for human and animal health. Considered an international benchmark in the vaccines research, Bionaturis Group closed last exercise with an increase of sales of 73% and a positive EBITDA of 29% compared to the previous year. The biotechnological Group which envisages a global access to health is listed on the Spanish stock exchange for SMEs (ticker BNT).

For further information about the event

September 1st, 2015|Blog english, congress|Comments Off on Bionaturis Group, at the KC Animal Health Investment Forum

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.